# Telix Pharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2025

- Company: [Telix Pharmaceuticals Ltd](/companies/tlx.md) (CIK 2007191)
- Form: 20-F
- Filed: 2026-02-20
- Accepted by EDGAR: Feb 19, 2026, 20:44 ET
- Period: 2025-12-31
- Accession: 0001628280-26-009943
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $803.8m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2025-01-01 to 2025-12-31 | $377.4m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2025-01-01 to 2025-12-31 | $426.4m | ifrs-full:GrossProfit |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | $29.8m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $1.9m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −$7.1m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −$0.02 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −$0.02 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$17.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2025-01-01 to 2025-12-31 | $25.7m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2025-12-31 | $141.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2025-12-31 | $330.3m | ifrs-full:CurrentAssets |
| Total assets | at 2025-12-31 | $1.16bn | ifrs-full:Assets |
| Current liabilities | at 2025-12-31 | $231.6m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2025-12-31 | $748.6m | ifrs-full:Liabilities |
| Shareholders' equity | at 2025-12-31 | $415.4m | ifrs-full:Equity |
| Shares outstanding | at 2025-12-31 | 338,777,049 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

Filed Feb 20, 2026.
Source: SEC EDGAR, the filing index for accession 0001628280-26-009943. Last ingested by Listed: Oct 29, 2026, 16:54 ET. No prices; not investment advice.